NXTC
NextCure, Inc.
Key Financials
Net Income
$-55844000
↓ 0.3%
Operating Income
$-57616000
↑ 3.6%
Revenue
$22.4M
0.0%
EPS (Diluted)
$-19.65
↓ 887.4%
Total Assets
$50.2M
↓ 37.9%
Total Liabilities
$15.2M
↓ 1.0%
Cash & Equivalents
$26.0M
↓ 6.3%
Shareholders' Equity
$34.9M
↓ 46.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| S-4/A | 10/1/2026 | View on SEC |
| 425 | 9/25/2026 | View on SEC |
| 8-K | 9/25/2026 | View on SEC |
| 8-K | 9/3/2026 | View on SEC |
| S-4 | 8/18/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| SCHEDULE 13G | 8/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NXTC |
| Company Name | NextCure, Inc. |
| CIK | 1661059 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 240-399-4900 |